English
This article is from Journal of Research in Medical Sciences : The Official Journal of Isfahan University of Medical Sciences , volume 17 . Abstract Background:: Patients with rheumatoid arthritis may be resistant to conventional treatment with disease-modifying antirheumatic drugs (DMARDs). On the other hand, biologic therapy is costly and may be inconvenient for many patients. Pamidronate is a potent bisphosphonate with the capacity of modifying the biological activity of the immune system cells. It may thus be used as an anti-inflammatory agent in patients with inflammatory joint diseases. Materials and Methods:: To assess the effectiveness of pamidronate in the management of rheumatoid arthritis, we selected 38 patients with rheumatoid arthritis to enroll in a pilot study to receive pamidronate and conventional treatment with prednisolone and DMARDs in combination. These patients received 60 mg of pamidronate for 3 consecutive months and were followed for 6 months since the first infusion. Results:: The mean visual analogue score (VAS) and disease activity score (DAS28) fell steadily until one month after the third infusion. However, no improvements were observed during the 3 m
Sign in with your free account to read, download EPUBs or listen.
Ebook · Intravenous pamidronate for refractory rheumatoid arthritis. · Salesi, Mansour, Mottaghi, Peyman, Karimifar, Mansour, Farajzadegan, Ziba · Internet Archive